查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1490035

全球抗病毒药物市场：按药物类别、类型、应用、分销管道、地区

Antiviral Drugs Market, By Drug Class, By Type, By Application, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 189 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计2024年全球抗病毒药物市场规模将达636.6亿美元，2024年至2031年复合年增长率为5.10%，2031年将达899.5亿美元。

报告范围 报告详情
基准年 2023年 2024年市场规模 636.6亿美元
实际资料 2019-2023 预测期 2024-2031
预测 2024-2031 年复合年增长率： 5.10% 2031 年金额预测 899.5亿美元
图：2024 年按地区分類的抗病毒药物市场占有率(%)
抗病毒药物市场-IMG1

过去几年，全球抗病毒药物市场稳定成长。抗病毒药，也称为抗病毒药物或感染疾病，是一类专门用于治疗病毒引起的感染疾病的药物。抗病毒药物透过抑制病毒的产生并防止病毒在体内传播来发挥作用。爱滋病毒/爱滋病、肝炎和流感等病毒性疾病的日益普及正在推动全球对抗病毒药物的需求。根据世界卫生组织 (WHO) 统计，2020 年全球约有 3,670 万人感染爱滋病毒。

市场动态：

全球抗病毒药物市场的成长是由病毒感染疾病和流行病发生率上升所推动的。 COVID-19大流行的出现进一步增加了对治疗抗病毒药物的需求。政府的有利支持和医疗保健设施支出的增加也推动了市场的成长。然而，与药物发现和开发相关的高成本以及严格的监管核准正在限制市场扩张。从积极的一面来看，增加新型抗病毒治疗的研发预计将在未来几年为参与者创造利润丰厚的机会。

本研究的主要特点

  • 该报告对全球抗病毒药物市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
  • 它还揭示了各个细分市场的潜在收益成长机会，并说明了该市场有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
  • 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球抗病毒药物市场的主要企业。
  • 主要企业包括 AbbVie Inc.、GSK plc、Dr. Reddy's Laboratories Ltd.、F. Hoffmann-La Roche Ltd.、Bristol-Myers Squibb Company、Cipla、Aurobindo Pharma、Gilead Sciences, Inc.、Merck & Group 和 Zydus。 、Atea Pharmaceuticals、Johnson & Johnson Services, Inc.、Sun Pharmaceutical Industries Ltd.、Pfizer Inc.、Torrent Pharmaceuticals Ltd.、Arbutus Biopharma、Divi's Laboratories Limited、RedHill Biopharma Ltd.、ViiV Healthcare Pty Ltd. 等。
  • 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球抗病毒药物市场迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 相关人员可以透过用于分析全球抗病毒药物市场的各种策略矩阵来促进决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章 市场动态、法规与趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 影响分析
  • 市场趋势
  • 主要进展
  • 监管场景
  • 收购和合作场景
  • 资金筹措和投资
  • PEST分析
  • 波特的分析

第四章全球抗病毒药物市场－COVID-19 的影响

  • 整体影响
  • 政府倡议
  • COVID-19 对市场的影响

第五章全球抗病毒药物市场：依药物类别，2019-2031（十亿美元）

  • DNA聚合酵素抑制剂
  • 逆转录酶抑制剂
  • 蛋白酶抑制剂
  • 神经氨酸酶抑制剂
  • 其他的

第六章 全球抗病毒药物市场：按类型划分，2019-2031（十亿美元）

  • 品牌
  • 非专利的

第七章 全球抗病毒药物市场：依应用分类，2019-2031（十亿美元）

  • HIV
  • 肝炎
  • 疱疹
  • 流感
  • 其他的

第八章 全球抗病毒药物市场：依分销管道划分，2019-2031（十亿美元）

  • 医院药房
  • 零售药房
  • 网路药房

第九章 全球抗病毒药物市场：按地区划分，2019-2031（十亿美元）

第10章竞争格局

  • 公司简介
    • AbbVie Inc.
    • GSK plc
    • Dr. Reddy's Laboratories Ltd.
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Cipla
    • Aurobindo Pharma
    • Gilead Sciences, Inc.
    • Merck &Co., Inc.
    • Zydus Group
    • Atea Pharmaceuticals
    • Johnson & Johnson Services, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Torrent Pharmaceuticals Ltd.
    • Arbutus Biopharma
    • Divi's Laboratories Limited
    • RedHill Biopharma Ltd.
    • ViiV Healthcare Pty Ltd.

第十一章分析师建议

第十二章参考文献与调查方法

简介目录
Product Code: CMI4912

Global antiviral drugs market is estimated to be valued at USD 63.66 Bn in 2024 and is expected to reach USD 89.95 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 63.66 Bn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 5.10% 2031 Value Projection: US$ 89.95 Bn
Figure. Antiviral Drugs Market Share (%), By Region, 2024
Antiviral Drugs Market - IMG1

The global antiviral drugs market has been witnessing steady growth over the past few years. Antiviral drugs, also known as antiviral agents or anti-infective medications, are a class of medication used specifically for treating infections caused by viruses. They work by inhibiting the production of viruses or preventing their spread in the body. Rising prevalence of viral diseases such as HIV/AIDS, hepatitis, influenza and others have been fueling demand for antiviral medications globally. According to the World Health Organization (WHO), around 36.7 million people were living with HIV worldwide in 2020.

Market Dynamics:

The global antiviral drugs market growth is driven by the growing incidence of viral infections and pandemics. The emergence of COVID-19 pandemic has further augmented the demand for antiviral drugs for treatment. Favorable government support and rising expenditure on healthcare facilities are also propelling the market growth. However, high costs associated with drug discovery and development as well as stringent regulatory approvals are restraining the market expansion. On the positive side, increasing R&D for developing novel antiviral therapeutics is expected to create lucrative opportunities for players in the coming years.

Key Features of the Study:

  • This report provides an in-depth analysis of the global antiviral drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global antiviral drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this includes AbbVie Inc., GSK plc, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Cipla, Aurobindo Pharma, Gilead Sciences, Inc., Merck & Co., Inc., Zydus Group, Atea Pharmaceuticals, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Torrent Pharmaceuticals Ltd., Arbutus Biopharma, Divi's Laboratories Limited, RedHill Biopharma Ltd., ViiV Healthcare Pty Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global antiviral drugs market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiviral drugs market.

Detailed Segmentation-

  • By Drug Class:
    • DNA Polymerase Inhibitors
    • Reverse Transcriptase Inhibitors
    • Protease Inhibitors
    • Neuraminidase Inhibitors
    • Others
  • By Type:
    • Branded
    • Generics
  • By Application:
    • HIV
    • Hepatitis
    • Herpes
    • Influenza
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AbbVie Inc.
    • GSK plc
    • Reddy's Laboratories Ltd.
    • Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Cipla
    • Aurobindo Pharma
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • Zydus Group
    • Atea Pharmaceuticals
    • Johnson & Johnson Services, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Torrent Pharmaceuticals Ltd.
    • Arbutus Biopharma
    • Divi's Laboratories Limited
    • RedHill Biopharma Ltd.
    • ViiV Healthcare Pty Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Type
    • Market Snapshot, By Application
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Antiviral Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Antiviral Drugs Market, By Drug Class, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • DNA Polymerase Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Reverse Transcriptase Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Protease Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Neuraminidase Inhibitors
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Antiviral Drugs Market, By Type, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Branded
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Generics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Antiviral Drugs Market, By Application, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • HIV
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Hepatitis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Herpes
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Influenza
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Antiviral Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Antiviral Drugs Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2019-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
      • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
      • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
      • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
      • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Company Profiles
    • AbbVie Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • GSK plc
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Dr. Reddy's Laboratories Ltd.
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Cipla
    • Aurobindo Pharma
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • Zydus Group
    • Atea Pharmaceuticals
    • Johnson & Johnson Services, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Torrent Pharmaceuticals Ltd.
    • Arbutus Biopharma
    • Divi's Laboratories Limited
    • RedHill Biopharma Ltd.
    • ViiV Healthcare Pty Ltd.

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact